The guidelines for fertility-preserving therapy in endometrial carcinomas are recommended for endometrioid adenocarcinomas cT1A, G1 without infiltration of the myometrium, and with the expression of progesterone receptors. The gene discussed is PGR; the disease is endometrial carcinoma.